Freudenberg Medical

launched LUBRITEQ, a new high-performance hydrophilic coating solution, in February 2026, positioned as a CDMO partner uniting advanced chemistry, device engineering and customer-first partnerships.

Country
Germany
Hydrophilic coating CDMO eu
Coverage
CNEUUS
consumables
diagnostics-medtech
regenerative-personalized
Regulatorsfdaemanmpa

Verifiable facts

FactValueSource
Headcount2,397 employees worldwide as of March 2026freudenbergmedical.com · mpo-mag.com
Revenue€11.73 billion for the Freudenberg Group in 2025freudenberg.com
Production siteAachen (Germany), Carrick-on-Shannon (Ireland), Minnetonka (MN, USA), and Jeffersonville (IN, USA) identified as Centers of Excellence for coatings; 12 total sites globallyfreudenbergmedical.com · mpo-mag.com
CapacitySupports over 1 million medical devices each year for functional surface coatingsfreudenbergmedical.com · medicaldesignandoutsourcing.com · mpo-mag.com
Regulatory approvalLUBRITEQ is USP 788 compliant and supported by an available FDA Master Filefreudenbergmedical.com · mpo-mag.com

Independent sources: medicaldesignandoutsourcing.com · mpo-mag.com

Technologies
NameClusterRisk
Biocompatible coatings for medical devicesdiagnostics-medtechLow
Bioprocess tubingconsumablesLow
Medical devices with biointerfaceregenerative-personalizedMedium

Compiled by BIOECON from primary sources.

Compliance Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.